Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 605 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Qué saber sobre los diferentes tipos de mastectomías para el cáncer... November 15, 2023 Prostate cancer: Lessons Learned from My Breast Cancer June 23, 2021 New insights on self-sampling for cervical cancer screening April 27, 2022 EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to... March 14, 2025 Load more HOT NEWS New on NCI’s Websites for March 2023 First Study Examining Mental Illness and Self-Harm Events Across 26 Cancer... FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities
